

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

Europäisches
PatentamtEuropean
Patent OfficeOffice européen
des brevets

REC'D 15 NOV 1999

WIPO PCT

09/787000

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

98870203.1

**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

08/11/99

Patent Application

Serial No. 08
1,311,087

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°: 98870203.1

Anmeldetag:
Date of filing:
Date de dépôt: 24/09/98

Anmelder:
Applicant(s):
Demandeur(s):
INNOGENETICS N.V.
9052 Gent
BELGIUM

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Rapid identification of microorganisms causing acute respiratory tract infections (ARI)

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
C12Q1/68

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

Rapid identification of microorganisms causing acute respiratory tract infections (ARI)

The present invention relates to the field of detection of micro organisms, more particularly detection of acute respiratory tract infections.

Acute respiratory tract infections (ARIs) are the most common cause of childhood morbidity and mortality worldwide, accounting for about 30% of all childhood deaths in the developing world (19). While rarely causing death in industrialized countries, ARIs cause enormous direct and indirect health care costs (10, 35, 4). The causative agents of ARIs encompass a wide variety of microorganisms. *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis* (2) are the most common bacteria encountered. As commensals of the upper respiratory tract they usually contaminate sputum samples, nasopharyngeal aspirates or swabs and thus their etiological role in ARIs is difficult to prove by upper respiratory tract sampling, unless invasive techniques (lung puncture) are used (34, 24).

In contrast to these bacteria, detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and also the detection of viruses in a child with respiratory symptoms is usually considered as evidence of acute infection. Current methods to identify these agents include cell culture, rapid antigen detection assays, serology (indirectly) and recently, PCR (34, 31). Cell culture techniques require specialized laboratories, are expensive, time consuming and labor intensive. Rapid antigen assays are available for a few microorganisms only (Influenza A and RSV in most countries). Serology usually requires documentation of a rise of antibody concentration from an acute to a convalescent blood sample and thus test results come in too late to be of relevance for the treatment of acute disease. While currently no rapid method for microbiological diagnosis of ARI is available for routine use, availability of such a test

reduced costs, less side effects as well as in a reduction of the emergence of resistance (38).

Currently available nucleic acid amplification techniques such as PCR (29) and RT-PCR are highly sensitive techniques for the detection of nucleic acid sequences from viruses and bacteria in clinical specimens (30, 21). These amplification techniques are particularly advantageous for detecting fastidious or "difficult to culture" organisms such as the respiratory syncytial virus (25) or *M. pneumoniae* (37). Previous studies using PCR and RT-PCR for the diagnosis of ARIs have focused on the detection of a single virus or bacterium; however, the diagnostic utility of nucleic acid amplification techniques for a single infectious agent is limited by the inability to establish a specific etiology whenever the result is negative and by the inability to document simultaneous infections involving more than one infectious organism. Published multiplex-PCR assays for the simultaneous detection of pathogens (15, 16, 23) and multiplex-RT-PCR assays (7, 36, 6) have only included two or three different organisms. The application of a RT-PCR panel to respiratory specimens as described by Gilbert et al. (13) has the disadvantage of different and time consuming assay conditions for each detected organism and the use of several tubes for one sample, thus enlarging the risk of cross-contamination.

Our strategy to overcome these limitations was to use a multiplex-RT-PCR protocol that allows the simultaneous detection of respiratory pathogens within one working day including RNA-viruses (enteroviruses, influenza A and B viruses, parainfluenzavirus type 1 and 3, respiratory syncytial virus), a DNA-virus (adenovirus) and bacteria (*C. pneumoniae*, *M. pneumoniae*) that do not usually colonize the upper respiratory tract of children.

The aim of the present invention is to provide methods and kits for detecting acute respiratory tract infections.

More particularly it is an aim of the present invention to provide a multiplex PCR method and kit for detecting acute respiratory tract infections.

It is also an aim of the present invention to provide primers and probes useful for detecting acute respiratory tract infections.

More particularly the present invention relates to a method for the detection of acute respiratory tract infection comprising the simultaneous amplification of several target nucleotide sequences present in a biological sample by means of a primer mixture comprising at least one primer set from each one of the following gene regions:

- the F1 subunit of the fusion glycoprotein gene for RSV,
- the hemagglutininneuraminidase gene for PIV-1,
- the 5' noncoding region of the PIV-3 fusion protein gene,
- 16 S rRNA sequence for M. Pneumoniae,
- 16S rRNA sequence for C. Pneumoniae,
- the 5' noncoding region for enterovirus,
- the non-structural protein gene from influenza A,
- the non-structural protein gene from influenza B, and,
- the hexon gene for adenoviruses.

This multiplex RT-PCR method is particularly preferred because it allows to determine the presence of the following micro organisms which infect the respiratory tract of mainly children in one amplification step: RSV, parainfluenza virus, M. pneumoniae, C. pneumoniae, enterovirus, influenza A and B and adenoviruses.

According to an alternative embodiment, the present invention also relates to a method as defined above in which human parainfluenza virus, influenza A and B, RSV and at least one of the following micro organisms are detected by means of a multiplex RT-PCR using primer pairs from the regions specified above : M. pneumoniae, C. pneumoniae, enterovirus or adenovirus.

According to an alternative embodiment, the present invention also relates to a method as defined above in which human parainfluenza virus, influenza A and B, RSV and at least two of the following micro organisms are detected by means of RT-PCR

using primer pairs from the regions specified above: *M. pneumoniae*, *C. pneumoniae*, enterovirus or adenovirus.

According to an alternative embodiment, the present invention also relates to a method as defined above in which human parainfluenza virus, influenza A and B, RSV and at least two of the following micro organisms are detected by means of RT-PCR using primer pairs from the regions specified above: *M. pneumoniae*, *C. pneumoniae*, enterovirus or adenovirus.

According to a preferred embodiment, the present invention relates to a method as defined above wherein said 16S rRNA primers are replaced by primers from the spacer region between the 16S and the 23S rRNA sequences.

According to another embodiment, the present invention relates to a method as defined above wherein in addition also at least one primer pair for the specific detection of *B. Pertussis* and *B. Parapertussis* are used, with said primers being preferably from the spacer region between the 16S and 23S rRNA sequences.

According to another embodiment, the present invention relates to a method as defined above wherein said primers are chosen from Table 2 or Table 4.

According to another embodiment, the present invention relates to a method as defined above wherein said amplified products are subsequently detected using a probe, with said probe being preferably selected from Table 3 or 4.

According to another embodiment the present invention relates to a primer chosen from Table 2 or Table 4.

According to another embodiment, the present invention relates to a probe chosen from table 3 or 4.

According to another embodiment, the present invention relates to a kit for the detection of acute respiratory tract infection comprising a set of primers for performing a method as defined above. Besides said primers, such a kit may also contain probes as well as the necessary buffers for achieving the amplification and possible hybridization reactions as well as a kit insert.

According to another embodiment, the present invention relates to a kit for the detection of acute respiratory tract infection comprising a set of probes for performing a method as defined above.

According to another embodiment, the present invention relates to a kit as defined above, wherein said probes are applied as parallel lines on a solid support, preferably on a nylon membrane, preferably a LiPA kit (see examples section and below).

Different techniques can be applied to perform the methods of the present invention. These techniques may comprise immobilizing the target polynucleic acids, after amplification, on a solid support and performing hybridization with labelled oligonucleotide probes. Alternatively, the probes may be immobilized on a solid support and hybridization may be performed with labelled target polynucleic acids, possibly after amplification. This technique is called reverse hybridization. A convenient reverse hybridization technique is the line probe assay (LiPA, Innogenetics, Belgium). This assay uses oligonucleotide probes immobilized as parallel lines on a solid support strip. It is to be understood that any other technique for detection of the above-mentioned co-amplified target sequences also covered by the present invention. Such a technique can involve sequencing methods known in the art.

The following definitions and explanations will permit a better understanding of the present invention.

The target material in the samples to be analysed may either be DNA or RNA, e.g. genomic DNA, messenger RNA or amplified versions thereof. These molecules are in this application also termed "polynucleic acids".

Well-known extraction and purification procedures are available for the isolation of RNA or DNA from a sample (e.g. in Sambrook et al., 1989).

The term "probe" according to the present invention refers to a single-stranded oligonucleotide which is designed to specifically hybridize to the target polynucleic acids. Preferably, the probes of the invention are about 5 to 50 nucleotides long, more preferably from about 10 to 25 nucleotides. Particularly preferred lengths of probes include 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. The nucleotides as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridization characteristics.

The term "primer" refers to a single stranded oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied. The length and the sequence of the primer must be such that they allow to prime the synthesis of the extension products. Preferably the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions at which the primer is used, such as temperature and ionic strength. It is to be understood that the primers of the present invention may be used as probes and *vice versa*, provided that the experimental conditions are adapted. The expression "suitable primer pair" in this invention refers to a pair of primers allowing specific amplification of a specific target polynucleic acid fragment.

The term "target region" of a probe or a primer according to the present invention is a sequence within the polynucleic acids to be detected to which the probe or the primer is completely complementary or partially complementary (i.e. with some degree of mismatch). It is to be understood that the complement of said target sequence is also a suitable target sequence in some cases.

"Specific hybridization" of a probe to a target region of a polynucleic acid means that said probe forms a duplex with part of this region or with the entire region under the experimental conditions used, and that under those conditions said probe does not form a duplex with other regions of the polynucleic acids present in the sample to be analysed.

"Specific hybridization" of a primer to a target region of a polynucleic acid means that, during the amplification step, said primer forms a duplex with part of this region or with the entire region under the experimental conditions used, and that under those conditions said primer does not form a duplex with other regions of the polynucleic acids present in the sample to be analysed. It is to be understood that "duplex" as used hereby, means a duplex that will lead to specific amplification.

The fact that amplification primers do not have to match exactly with the corresponding target sequence in the template to warrant proper amplification is amply documented in the literature (Kwok et al., 1990). However, when the primers are not completely complementary to their target sequence, it should be taken into account that

the amplified fragments will have the sequence of the primers and not of the target sequence. Primers may be labelled with a label of choice (e.g. biotine). The amplification method used can be either polymerase chain reaction (PCR; Saiki et al., 1988), ligase chain reaction (LCR; Landgren et al., 1988; Wu & Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA; Guatelli et al., 1990; Compton, 1991), transcription-based amplification system (TAS; Kwoh et al., 1989), strand displacement amplification (SDA; Duck, 1990) or amplification by means of Q β replicase (Lomeli et al., 1989) or any other suitable method to amplify nucleic acid molecules known in the art.

Probe and primer sequences are represented throughout the specification as single stranded DNA oligonucleotides from the 5' to the 3' end. It is obvious to the man skilled in the art that any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U).

The probes according to the invention can be prepared by cloning of recombinant plasmids containing inserts including the corresponding nucleotide sequences, if need be by excision of the latter from the cloned plasmids by use of the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight. The probes according to the present invention can also be synthesized chemically, for instance by the conventional phospho-triester method.

The oligonucleotides used as primers or probes may also comprise nucleotide analogues such as phosphorothiates (Matsukura et al., 1987), alkylphosphorothiates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984). As most other variations or modifications introduced into the original DNA sequences of the invention these variations will necessitate adaptations with respect to the conditions under which the oligonucleotide should be used to obtain the required specificity and sensitivity. However the eventual results of hybridization will be essentially the same as those obtained with the unmodified oligonucleotides. The introduction of these modifications may be advantageous in order to positively influence characteristics such as hybridization kinetics, reversibility of the hybrid-formation, biological stability of the oligonucleotide molecules, etc.

The term "solid support" can refer to any substrate to which an oligonucleotide probe can be coupled, provided that it retains its hybridization characteristics and provided that the background level of hybridization remains low. Usually the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead) or a chip. Prior to application to the membrane or fixation it may be convenient to modify the nucleic acid probe in order to facilitate fixation or improve the hybridization efficiency. Such modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH_2 groups, SH groups, carboxylic groups, or coupling with biotin, haptens or proteins.

The term "labelled" refers to the use of labelled nucleic acids. Labelling may be carried out by the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki et al. (1988) or Bej et al. (1990) or labelled primers, or by any other method known to the person skilled in the art. The nature of the label may be isotopic (^{32}P , ^{35}S , etc.) or non-isotopic (biotin, digoxigenin, etc.).

The term "biological sample or sample" refers to for instance naso-pharyngeal aspirates, throat or nasopharyngeal swabs, nasopharyngeal washes or tracheal aspirates or other respiratory tract sample comprising DNA or RNA.

For designing probes with desired characteristics, the following useful guidelines known to the person skilled in the art can be applied.

Because the extent and specificity of hybridization reactions such as those described herein are affected by a number of factors, manipulation of one or more of those factors will determine the exact sensitivity and specificity of a particular probe, whether perfectly complementary to its target or not. The importance and effect of various assay conditions are explained further herein.

****The stability of the [probe : target] nucleic acid hybrid should be chosen to be compatible with the assay conditions. This may be accomplished by avoiding long AT-rich sequences, by terminating the hybrids with G:C base pairs, and by designing the probe with an appropriate T_m . The beginning and end points of the probe should be chosen so that the length and %GC result in a T_m about $2-10^\circ\text{C}$ higher than the temperature at which the final assay will be performed. The base composition of the**

probe is significant because G-C base pairs exhibit greater thermal stability as compared to A-T base pairs due to additional hydrogen bonding. Thus, hybridization involving complementary nucleic acids of higher G-C content will be more stable at higher temperatures.

****Conditions such as ionic strength and incubation temperature under which a probe will be used should also be taken into account when designing a probe. It is known that the degree of hybridization will increase as the ionic strength of the reaction mixture increases, and that the thermal stability of the hybrids will increase with increasing ionic strength. On the other hand, chemical reagents, such as formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds, will increase the stringency of hybridization. Destabilization of the hydrogen bonds by such reagents can greatly reduce the T_m . In general, optimal hybridization for synthetic oligonucleotide probes of about 10-50 bases in length occurs approximately 5°C below the melting temperature for a given duplex. Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity.**

****It is desirable to have probes which hybridize only under conditions of high stringency. Under high stringency conditions only highly complementary nucleic acid hybrids will form; hybrids without a sufficient degree of complementarity will not form. Accordingly, the stringency of the assay conditions determines the amount of complementarity needed between two nucleic acid strands forming a hybrid. The degree of stringency is chosen such as to maximize the difference in stability between the hybrid formed with the target and the non-target nucleic acid.**

****Regions in the target DNA or RNA which are known to form strong internal structures inhibitory to hybridization are less preferred. Likewise, probes with extensive self-complementarity should be avoided. As explained above, hybridization is the association of two single strands of complementary nucleic acids to form a hydrogen bonded double strand. It is implicit that if one of the two strands is wholly or partially involved in a hybrid that it will be less able to participate in formation of a new hybrid. There can be intramolecular and intermolecular hybrids formed within the molecules of one type of probe if there is sufficient self complementarity. Such structures can be**

avoided through careful probe design. By designing a probe so that a substantial portion of the sequence of interest is single stranded, the rate and extent of hybridization may be greatly increased. Computer programs are available to search for this type of interaction. However, in certain instances, it may not be possible to avoid this type of interaction.

**Standard hybridization and wash conditions are disclosed in the Materials & Methods section of the Examples. Other conditions are for instance 3X SSC (Sodium Saline Citrate), 20% deionized FA (Formamide) at 50°C. Other solutions (SSPE (Sodium saline phosphate EDTA), TMAC (Tetramethyl ammonium Chloride), etc.) and temperatures can also be used provided that the specificity and sensitivity of the probes is maintained. When needed, slight modifications of the probes in length or in sequence have to be carried out to maintain the specificity and sensitivity required under the given circumstances.

The term "hybridization buffer" means a buffer allowing a hybridization reaction between the probes and the polynucleic acids present in the sample, or the amplified products, under the appropriate stringency conditions.

The term "wash solution" means a solution enabling washing of the hybrids formed under the appropriate stringency conditions.

Figure Legends

Figure 1. Separation of m-RT-PCR products on Agarose Gel.

10 μ l of m-RT-PCR products were separated on 2 % agarose gel. The m-RT-PCR was performed using 1 μ l of viral or bacterial nucleic acid as template as described in material and methods. The expected product lengths are given in the text. DNA fragment size of marker (0.7 μ g of *Msp*I digested pUC19) in base pairs (bp) is 1: 501 bp; 2: 404 bp; 3: 331 bp; 4: 242 bp; 5: 190 bp; 6: 147 bp; 7: 110 bp.

Figure 2. Proportion of positive m-RT-PCR results.

The number of positive m-RT-PCR results and total samples is given on the y-axis. The time scale on the x-axis is from November 1995 to April 1998.

Figure 3. Frequency of positive m-RT-PCR-ELISA results in clinical specimens.

The number of positive m-RT-PCR results for each of the nine organisms is given on the y-axis. The time scale on the x-axis is from November 1995 to April 1998.

Figure 4. Percentage of organisms causing infections.

The amount of organisms causing a respiratory disease is given in percent of the total of organisms causing the according disease. Organisms not included in the test are not shown in the figure.

Figure 5 shows the separation on a 2% agarosegel of the amplicons obtained after multiplex-RT-PCR on reference material shows discrete bands of the expected size for all organisms tested.

Figure 6 shows hybridization results of these amplicons with the LiPA strips as well as a negative control. These results clearly demonstrate that all the probes on the strip react specifically with their corresponding amplicons and no cross-hybridization is seen between the different organisms tested.

EXAMPLES

Example 1

MATERIALS AND METHODS

Abbreviations. Acute respiratory tract infection (ARI); reverse transcription combined with PCR (RT-PCR); multiplex-RT-PCR (m-RT-PCR); m-RT-PCR combined with microwell hybridization assay (m-RT-PCR-ELISA); influenza virus type A (influenza A or InfA); Influenzavirus type B (influenza B or InfB); parainfluenzavirus type 1 (PIV-1); parainfluenzavirus type 3 (PIV-3); respiratory syncytial virus (RSV).

Patient samples. Nasopharyngeal aspirates were obtained from children hospitalized with ARI at our institution in the time between November 1995 through April 1998. Diagnoses included pneumonia, wheezing bronchitis, bronchitis, laryngotracheitis (the latter encompassing laryngitis, laryngo-tracheo-bronchitis and (pseudo-) croup), pharyngitis, tonsillitis, rhinitis, conjunctivitis, otitis media and were obtained from the computer-based discharge-diagnosis data base of the hospital. While specimen collection was not complete during the first winter season (November 1995 to April 1996), it was > 95% complete for the remaining time as October 1st, 1996. Specimens were collected the first working day following hospitalization, directly brought to the laboratory, initially stored at 4°C, prepared for testing and afterwards or for longer storage frozen at minus 70°C. Samples were split with appropriate precautions to avoid contamination and one portion was used directly for detection of RSV and influenza type A antigen by the use of enzyme immuno assays (EIA) (Becton Dickinson, Heidelberg, Germany). A second portion was used for m-RT-PCR followed by agarose gel electrophoresis and specification in a microwell hybridization assay.

Nucleic acid extraction. Samples received from November 1995 through July 1997 were prepared as follows. Total nucleic acids were obtained from 100 µl of respiratory specimens diluted with 100 µl 0.9% NaCl-solution. Sodiumdodecyl sulfate was added to a final concentration of 0.1%. Nucleic acid extraction was accomplished once with 1 volume of a 1:1 phenol-chloroform mixture and once with 1 volume chloroform and precipitated with 0.3 M ammonium acetate and ethanol. Nucleic acid pellets were dried and resuspended in 15 µl of diethylpyrocarbonate-treated, bidistilled water. Specimens received from August 1997 to April 1998 were prepared using the Boehringer "High Pure Viral Nucleic Acid Kit" following the instructions of the purchaser (Boehringer Mannheim, Mannheim, Germany).

Controls for the preparation procedure were as follows: One negative sample (sputa from healthy persons) was included in each series of 5-10 samples to monitor for potential cross-contamination. In case of a false positive result in the negative control, the m-RT-PCR was repeated on all positive clinical samples in that series with another portion of the clinical specimen. Positive controls from culture (influenza A, influenza B, PIV-1, PIV-3 or RSV respectively) were used in each test to document the efficiency of the preparation procedure. Prepared samples were used immediately for m-RT-PCR and remaining aliquots were stored at minus 70°C.

Multiplex-RT-PCR. Target sequences were coding/non-coding regions, respectively, of: F1 subunit of the fusion glycoprotein gene for RSV, hemagglutinin-neuraminidase gene for PIV-1, 5' noncoding region of the PIV-3 fusion protein gene; nucleotide sequence of the 16S ribosomal RNA for *M. pneumoniae*, nucleotide sequence of the 16S ribosomal RNA for *C. pneumoniae*; an among enteroviruses highly conserved 5' noncoding region for enterovirus, non-structural protein gene

from influenza A and influenza B and sequence of the hexon gene for adenoviruses. Sequences were selected from procedures described previously (25, 20, 9, 27, 11, 37, 3, 18). For adenovirus the sequence of probe A was used as second amplification primer instead of primer 2 (18).

Five to six μ l of the nucleic acid preparations from clinical specimens were included in the reverse transcription (RT) reaction in a final volume of 20 μ l. The RT was performed for 60 min at 37°C with the following buffer composition: 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂, 10 mM DTT, 1 mM (each) deoxynucleoside triphosphates (Pharmacia Biotech, Uppsala, Sweden), 0.2 μ g/ μ l hexanucleotide mix (Boehringer Mannheim, Mannheim, Germany), 20 U RNAsin (Promega, Madison, Wisconsin USA) and 10 U of Moloney murine leukemia virus reverse transcriptase (Eurogentec, Seraing, Belgium).

After heat inactivation of reverse transcriptase at 90°C for 5 min, the entire 20- μ l RT reaction mixture was used for multiplex PCR in a total volume of 80 μ l. The buffer composition (without consideration of the RT-buffer) was 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 0.2 mM dATP, dCTP, dGTP, 0.2 mM dTTP, 0.01 mM digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany), 1 μ M (each) primer (Eurogentec, Seraing, Belgium), and 5 U of AmpliTaq-Gold polymerase (Perkin-Elmer, Branchburg, NJ, USA). PCR was performed on a PE 9600 Thermocycler (Perkin-Elmer, Branchburg, NJ, USA) as follows: 40 cycles of denaturation at 94°C for 30 sec (10 min during cycle 1), annealing at 50°C for 30 sec and extension at 72°C for 30 sec (7 min during cycle 40).

As negative control blank reagent that contained H₂O was used instead of nucleic acid. As positive m-RT-PCR control total cellular nucleic acid extracted from virus and/or bacterial stocks was used.

Prevention of carry-over contamination. To prevent carry-over contamination within the laboratory, the following precautions were taken: All purchased reagents were split into small aliquots. The preparation of PCR reagents, the extraction of nucleic acids from clinical samples and the amplification step were conducted in three different rooms. Tips equipped with sealing filters (safeseal-tip from BIOzym, Hess. Oldendorf, Germany) were used for pipetting reagents introduced into the PCR and all areas and equipment were decontaminated with sodiumhypochlorite and Bacillol (an alcoholic disinfectant from: Bode Chemie, Hamburg, Germany) prior to and after pipetting.

Agarose gel electrophoresis. Electrophoretic separation of PCR products (10 µl) was performed for 30 minutes at 130 to 160 mA on 2% agarose gels in 0.5 x TBE buffer (0.045M Tris-borate, 0.001M EDTA), stained with ethidium bromide and PCR products were visualized by UV illumination as described by Sambrook et al. (32). For control of fragment lengths, 0.6 –0.8 µg of *MspI* digested pUC19 DNA was applied as marker.

Microwell hybridization analysis. This assay was performed using the PCR-ELISA system from Boehringer Mannheim (Mannheim, Germany). Nine wells of a streptavidin-coated microtiter plate were each filled with 5 µl of PCR product and denatured by adding 25 µl of 0.2 N NaOH to each well. After 5 minutes 200 µl hybridization buffer containing 2 pmol of the respective biotinylated capture probe

was added. The capture probes used were specific for the amplified target sequences (see above) and the sequences of the probes for enterovirus, influenza A, influenza B, PIV-1, adenovirus (probeB) and *M. pneumoniae* (Gpo1) were identical to previously reported sequences (9, 27, 3, 18, 37). The sequences of probes used for the others are (5'-CCT GCA TTA ACA CTA AAT TC-3' for RSV; 5'-TCT TGC TAC CTT CTG TAC TAA-3' for *C. pneumonia* and 5'-AAA ATT CCA AAA GAG ACC GGC-3' for PIV-3). All capture probes were 3'-biotinylated and purchased by Eurogentec (Seraing, Belgium). Capture was allowed to proceed for 1 h at 37°C, and afterwards the wells were washed four times with 200 µl of washing solution (Boehringer Mannheim, Mannheim, Germany) at room temperature. To each well 200 µl of anti-DIG-peroxidase (10 mU/ml, Boehringer Mannheim, Mannheim, Germany) diluted 1/1,000 in a buffer containing 100 mM Tris-HCl, 150 mM NaCl (pH 7.5) was added. Plates were incubated for 30 min at 37 °C and wells were washed four times with washing solution. 200 µl ABTS[®] substrate solution (Boehringer Mannheim, Mannheim, Germany) was added, and the wells were incubated for 30 min at 37°C. The optical density (OD) was read on a DIAS reader (Dynatech Laboratories, Guernsey, Channel Islands) at 405 nm (reference filter 492 nm). The run was considered valid, if all negative control values were less than 0.2 OD units and the positive control was higher than 1.0 OD units. Samples were classified as PCR-positive or negative according to a cutoff OD value of 0.5 and by comparison with the results from gel electrophoresis. Samples with initial readings of between 0.2 and 0.5 were considered borderline and were classified as positive or negative only after retesting with the specific single primer set. Positive hybridization controls were included in each microwell hybridization assay. They consisted of PCR products derived from the positive controls that were included in the m-RT-PCR.

Administration of Data. All data obtained were managed in a Microsoft Access database. This database included all available information about patients as well as all diagnostic data and results from m-RT-PCR-ELISA, and in case of influenza A and RSV the data of the EIA.

Bacterial and viral stocks. Bacterial and viral stocks used as positive control were kindly provided by the following persons: B. Schweiger and E. Schreier, (Robert-Koch-Institute, Berlin) enteroviruses, influenza A and influenza B; K.M. Edwards (Vanderbilt University, Tennessee, USA) RSV, PIV-1, PIV-3; A. Strecker (Institute for Virology, Bochum) RSV-long, PIV-3; R. Krausse and P. Rautenberg (Institute for Medical Microbiology, Kiel) *M. pneumoniae*, *C. pneumoniae*, adenoviruses.

The exact number of viruses or bacteria within these samples was not known and was assumed to be at most 10^6 /ml as stated by B. Schweiger and P. Rautenberg (personal communication). For preliminary sensitivity testing of m-RT-PCR consecutive dilutions (tenfold steps) of prepared nucleic acids from these cultures were used as template for m-RT-PCR and for amplification with single primer sets. Due to unavailable information about the exact number of viruses and bacteria the probable amount of nucleic acids which was sufficient to result in an amplification product was calculated based on the assumed particle number (10^6 /ml undiluted sample). To detect possible cross reactivity among the organisms one μ l of undiluted nucleic acid from each organism was used in a m-RT-PCR.

RESULTS

Multiplex RT-PCR on bacterial and viral nucleic acids. The m-RT-PCR-ELISA procedure was tested with nucleic acids prepared from the stock solutions as described in material and methods. As can be seen in figure 1 only one specific amplification product could be observed in each lane. The predicted sizes of the amplification products (*C. pneumoniae*, 463 bp; *M. pneumoniae*, 277 bp; influenza B, 249 bp; RSV, 239 bp; PIV-3, 205 bp; influenza A, 190 bp; PIV-1, 179 bp; enterovirus, 154 bp; adenovirus, 134 bp) were in good agreement with the fragment sizes calculated from the agarose gel (Fig. 1). This suggests that the m-RT-PCR yielded specific products. However, differentiation of influenza A and PIV-3 by fragment size in gel electrophoresis alone is difficult, but the absorbance values obtained by the PCR-ELISA test confirmed this specificity. Unconsumed primers are visible at the bottom of the gel.

In order to estimate the sensitivity of the m-RT-PCR concentrated virus stock solutions were diluted consecutively in 10-fold steps and tested with specific primer pairs to produce amplification products visible on agarose gel which were specified in the PCR-ELISA. Assuming that a maximum of 10^8 of the respective microorganisms per ml were present in the original stock solution, it was calculated that the method was able to detect 1 target sequence of *M. pneumoniae* and 1 target sequence of *C. pneumoniae*, 10 copies of adenovirus DNA and enterovirus RNA, 100 copies of PIV-1, PIV-3, influenza A, influenza B and RSV -RNA in the analogs m-RT-PCR reaction.

Comparison of Enzyme Immuno Assay (EIA) with m-RT-PCR-ELISA. To receive information about the quality of the m-RT-PCR-ELISA we compared results obtained

with those from commercial EIA's. With this EIA 940 clinical specimens were tested for the presence of influenza A and 1,031 clinical specimens for the presence of RSV. Results are summarized in table 1. The overall accordance was 95% of PCR results for RSV to those obtained by EIA (with 140 positive + 891 negative specimens in EIA as reference = 100%). 25 specimens were identified as RSV positive by PCR-ELISA only, 24 as RSV positive by EIA only. In case of influenza A the overall accordance of PCR to EIA was 98% (with 53 positive + 887 negative in EIA as reference = 100%) with 1 specimen positive by EIA only and 14 specimens positive by PCR ELISA only.

Results of m-RT-PCR-ELISA with clinical specimens. A total of 1,118 samples were tested by m-RT-PCR-ELISA. The number of samples tested over time and the proportion of positive PCR results can be taken from figure 2. The amount of specimens increased periodically during all cold seasons (from November to April) and this correlated with an increased number of positive PCR results. During the winter season 1996 / 1997 the maximum number of patient samples ($n = 106$) was received in February and detection of at least one microorganism by m-RT-PCR was accomplished in 48%. The lower number of specimens in the winter 1995 / 1996 was due to incomplete sample collection early during our test series. Results for the different microorganisms are shown in detail in figure 3. A total of 723 (65%) specimens were negative and 395 (35 %) were positive for at least one of the

organisms included in the test. Of the isolates 37.5% were RSV, 20.0% influenza A, 12.9 % adenoviruses, 10.6% enteroviruses, 8.1% *M. pneumoniae*, 4.3% PIV-3, 3.5% PIV-1, 2.8% influenza B and 0.2% *C. pneumoniae*, (based on total positive m-RT-PCR-ELISA). RSV and influenza A mainly were detected from December to May. For influenza B (February to April 1997) and for PIV-1 (September to December 1997) only one main peak was observed. Infection with adenovirus, enterovirus, PIV-3 and

M. pneumonia was detected more or less constantly over the time. *C. pneumoniae* was detected only once in January 1997.

Simultaneous detection of two organisms. The m-RT-PCR revealed evidence of simultaneous infection with two organisms in 20 cases (1.8% of the total or 5% of the positive specimens). Co-amplification of adenovirus nucleic acid sequence occurred with *C. pneumoniae* (1x), enterovirus (1x), Influenza A (1x) and RSV (5x). Dual infections involving enteroviruses were detected with adenovirus (1x), influenza A (3x), influenza B (1x), PIV-3 (3x), *M. pneumoniae* (1x) and with RSV (3x). Furthermore influenza B nucleic acid was co-amplified with RSV and *M. pneumoniae* with PIV-1 each in one specimen.

Clinical data. Clinical data were available as of February 1995 from 861 / 1,061 sample-patient pairs with second or following samples from the same hospital admission of one patient being excluded. From these 861 patients, 550 were between 0 to 2 years of age, 153 were between 2 to 5 years of age and 158 were older than 5 years. In 62% of those specimens no bacterial or viral nucleic acids could be detected by m-RT-PCR. The most frequent diagnosis in this hospital based study was pneumonia (309 cases or 36%). It was most commonly caused by RSV (n = 59), influenza A (n = 17), *M. pneumoniae* (n = 16) and adenovirus (n = 15). Enterovirus, PIV-3, PIV-1, and influenza B were associated with less than 10 pneumonia cases each. Among 167 patients with wheezing bronchitis (19% of 861 specimens) RSV was detected in 45 cases, adenovirus in 16 and enteroviruses, influenza A, influenza B, PIV-1, PIV-3 and *M. pneumoniae* in less than 10 cases each. Bronchitis was observed in a total of 95 patients (11% of the 861 specimens) and the detected organisms were RSV (13 cases), enterovirus and influenza A (4 cases each),

adenovirus (3 cases). Rhinitis was diagnosed in 7.1%, laryngotracheitis in 6.2%, and pharyngitis, otitis media, tonsillitis and conjunctivitis in less than 5% each of the 861 specimens tested with the detection of a microorganism by m-RT-PCR in less than 10 cases. Other diseases were diagnosed in 9.1% of the patients.

The frequency of detection of one of the nine organisms in the PCR for a given respiratory disease is shown in figure 4. RSV was most commonly associated with pneumonia, wheezing bronchitis, bronchitis, otitis media or pharyngitis. Influenza A was associated with more than 5% of the cases with of otitis media, tonsillitis, pharyngitis, laryngotracheitis, pneumonia; enteroviruses were associated with more than 5% of cases of tonsillitis, pharyngitis; adenoviruses were associated with pharyngitis, wheezing bronchitis, conjunctivitis and tonsillitis; *M. pneumoniae* most commonly associated with pneumonia, while PIV-1 was mainly associated with laryngotracheitis and PIV-3 with laryngotracheitis and conjunctivitis. *C. pneumonia* was detected only once in a patient with bronchitis.

Example 2 : LiPA application for acute respiratory tract infections

1. Design of oligonucleotide probes for LiPA application

Some of the oligonucleotide probes used in Example 1 were adapted in order to obtain good specificities and sensitivities for the different probes when used in a LiPA assay (Line Probe Assay, WO 94/12670). The following table summarizes the different probes for the organisms identified as originally described and their adapted versions for LiPA use.

Organism	Original probe	Adapted versions	Name*
Enterovirus	gaaacacggacacccaaagta	gaaacacggacacccaaagta	entero1
Influenza A	gtcctcatcgaggactgaatggaatgat	catcgaggactgaatgg	influa1
Influenza B	gtcaagagcaccgattatcac	gtcaagagcaccgattatcac	influb1
Adenovirus	ctcgatgacgccgcggtgc	gatgacgccgcggtg	adeno1
		tctcgatgacgccgcg	adeno2
		cataaagaaggggtgggc	adeno3
Parainfluenza 1	taccttcattatcaattggttaagtcaatatg	ccttcattatcaattggttaagtc	piv11
		ccttcattatcaattggtgatgc	piv12
		gtagaytaccttcattatcaattggt	piv13
Parainfluenza 3	aaaattccaaaagagaccggc	aaaattccaaaagagaccggc	piv31
RSV	cctgcattaacactaaattc	cacctgcattaacactaaattct	rsv1
M. pneumoniae	actcctacgggaggcagcagta	ctacgggaggcagcagt	mpn1
C. pneumoniae	tcttgctaccttctgtactaa	tcttgctaccttctgtactaa	cpn1

Table 3

* Probes in bold were finally used on first generation LiPA assay

Optimized probes were provided enzymatically with a poly-T-tail using terminal deoxynucleotidyl transferase (Pharmacia) in a standard reaction buffer. After one hour incubation, the reaction was stopped and the tailed probes were precipitated and washed with ice-cold ethanol. Probes were dissolved in 6x SSC at their respectively

specific concentrations and applied as horizontal lines on membrane strips. Biotinylated DNA was applied alongside as positive control. The oligonucleotides were fixed to the membrane by baking at 80°C for 12 hours. The membrane was then sliced into 4mm strips.

2. Nucleic acid preparation and PCR amplification

Bacterial and viral culture stocks were used as reference material. Nucleic acid was extracted according to standard procedures as described above.

One to five µl of the nucleic acid preparation was used in the multiplex-RT-PCR as described previously, with the exception that the cycle number was reduced to 35 and labeling of the amplicons was done by using biotinylated primers instead of the incorporation of digoxigenin-11-dUTP.

3. LiPA test performance

Equal volumes (5 to 10 µl) of the biotinylated PCR fragments and of the denaturation solution (400 mM NaOH/10 mM EDTA) were mixed in test troughs and incubated at room temperature for 5 min. Then, 2 ml of the 50°C prewarmed hybridization solution (2xSSC/0.1% SDS) was added followed by the addition of one strip per test trough. Hybridization occurred for 1 hour at 50°C in a closed shaking water bath. The strips were washed twice with 2 ml of stringent wash solution (2xSSC/0.1% SDS) at room temperature for 20 sec., and once at 50°C for 15 min. Following this stringent wash, strips were rinsed two times with 2 ml of the Innogenetics standard Rinse Solution (RS). Strips were incubated on a rotating platform with the alkaline phosphatase-labelled streptavidin conjugate, diluted in standard Conjugate Solution for 3 min. at room temperature. Strips were then washed twice with 2 ml of RS and once with standard Substrate Buffer (SB), and the colour reaction was started by adding BCIP and NBT to the SB. After 30 min. at room temperature, the colour reaction was stopped by replacing the colour compounds by distilled water. Immediately after drying, the strips were interpreted. The complete procedure described above can also be

replaced by the standard Inno-LiPA automation device (Auto-LiPA, Innogenetics, Zwijnaarde, Belgium).

Figure 5 shows the separation on a 2% agarosegel of the amplicons obtained after multiplex-RT-PCR on reference material shows discrete bands of the expected size for all organisms tested.

Figure 6 shows hybridization results of these amplicons with the LiPA strips as well as a negative control. These results clearly demonstrate that all the probes on the strip react specifically with their corresponding amplicons and no cross-hybridization is seen between the different organisms tested.

4. New probe development for *C. pneumoniae*, *M. pneumoniae*, *B. pertussis* and *B. parapertussis*.

To replace primers and probes (16S rRNA) used in the multiplex-RT-PCR for detection of *M. pneumoniae* and *C. pneumoniae*, a new set of primers and probes was developed for these organisms derived from the 16S-23S rRNA spacer region. Also primers and probes were developed for the specific detection of *B. pertussis* and *B. parapertussis* or *B. bronchiseptica* to add to the multiplex-RT-PCR.

In the table below the sequences of the primers and probes, derived from the 16S-23S rRNA spacer region for these bacterial pathogens are summarized.

Organism	Primers*	Probes
----------	----------	--------

Mycoplasma pneumoniae	FP1 : ggtggtacacctccttctaag	MPN3 : ggtaaattaaacccaaatccct
	FP2 : gtggtaaattaaacccaaatccc	MPN4 : gaacatttcgcttcttc
Chlamydia pneumoniae	RP : gcatccaccataagcccttag	MPN5 : gaacatttcgcttcttcaa
	FP : ccttttaaggacaaggaaggtg	CPN1 : gcaagtattttatattccgcatt
Bordetella pertussis	RP : gatccatgcaagtaactcacc	CPN2 : gtttcaaaacattcagtatatgatc
	FP : tatagctgctggatcggtgg	BP2 : gcctgtccagaggatg
Bordetella parapertussis/bronchiseptica	RP : ccaaaaccaacgcttaacac	BPP1 : cccgtcttgaagatggg
	idem B. pertussis	

Table 4

* : FP = forward primer; RP = reverse primer

PCR experiments demonstrated that all selected primersets specifically amplified the corresponding organisms and no amplicons were obtained using nucleic acids derived from phylogenetically related organisms or any of the other infectious agents detected in the multiplex-RT-PCR.

Biotinylated universal primers derived from the 3' end of the 16S rRNA and the 5' part of the 23S rRNA were used to amplify the 16S-23S rRNA spacer region of the bacteria of interest and their closest relatives.

Reverse hybridization on LiPA strips in 2x SSC/0.1% SDS at 50°C showed that all selected probes specifically reacted with the organisms of interest and no cross-reaction was seen with amplicons derived from the previously described multiplex-RT-PCR.

Initial experiments demonstrated that primers and probes (derived from the ribosomal spacer) can be implemented in the multiplex-RT-PCR to replace the currently used primers and probes for *M. pneumoniae* and *C. pneumoniae* and that the assay can be extended by adding primers and probes for *Bordetella* spp. involved in respiratory tract infections.

From these results it is anticipated that this set can be further extended with probes (more particularly from the 16S-23S rRNA spacer region) for other relevant pathogens such as *Legionella pneumophila*.

Table 1: Comparison of EIA and m-RT-PCR-ELISA

RSV	EIA		
		Pos.	Neg.
PCR	Pos.	116	25
	Neg.	24	866
	Total	140	891

InfA	EIA		
		Pos.	Neg.
PCR	Pos.	52	14
	Neg.	1	873
	Total	53	887

Table 2. Primer sequences used in Example 1

ENTERO-FP1:	att gtc acc ata agc agc ca-3'
ENTERO-RP1:	tcc tcc ggc ccc tga atg cg-3'
MPN-FP1:	aag gac ctg caa ggg ttc gt-3'
MPN-RP1:	ctc tag cca tta cct gct aa-3'
INFLUA-FP1:	aag ggc ttt cac cga aga gg-3'
INFLUA-RP1:	ccc att ctc att act gct tc-3'
INFLUB-FP1:	atg gcc atc gga tcc tca ac-3'
INFLUB-RP1:	tgt cag cta tta tgg agc tg-3'
ADENO-FP1:	gcc gag aag ggc gtg cgc agg ta-3'
ADENO-RP1:	atg act ttt gag gtg gat ccc atg ga-3'
CPN-FP1:	tga caa ctg tag aaa tac agc-3'
CPN-RP1:	cgc ctc tct cct ata aat-3'
PIV1-FP1:	cac atc ctt gag tga tta agt ttg atg a-3'
PIV1-RP1:	att tct gga gat gtc ccg tag gag aac-3'
PIV3-FP1:	tag cag tat tga agt tgg ca-3'
PIV3-RP1:	aga ggt caa tac caa caa cta-3'
RSV-FP1:	tgt tat agg cat atc att ga-3'
RSV-RP1:	tta acc agc aaa gtg tta ga-3'

REFERENCES

1. Adcock, P. M., G. G. Stout, M. A. Hauck, and G. S. Marshall. 1997. Effect of rapid viral diagnosis on the management of children hospitalized with lower respiratory tract infection. *J. Pediatric. Infect. Dis.* **16**: 842 – 846.
2. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. *NEJM.* **333**:1618-1624.
3. Claas, E. C. J., M. J. W. Sprenger, G. E. M. Kleter, R. van Beek, W. G. V. Quint, and N. Masurel. 1992. Type-specific identification of influenza viruses A, B and C by the polymerase chain reaction. *J. Virol. Meth.* **39**:1-13.
4. Dixon, R. E. 1985. Economic costs of respiratory infections in the United States. *Am. J. Med.* **78** (Suppl. 6B):45-51.
5. Draws, A. L., R. L. Atmar, W. P. Glezen, B. D. Baxter, P. A. Piedra, S. B. Greenberg. 1997. Dual respiratory virus infections. *Clin. Infect. Dis.* **25**:1421-1429.
6. Echevarria, J. E., D. D. Erdman, E. M. Swierkosz, B. P. Holloway, L. J. Anderson. 1998. Simultaneous detection and identification of human parainfluenza viruses 1, 2, and 3 from clinical samples by multiplex PCR. *J. Clin. Microbiol.* **36**:1388-1391.
7. Ellis, J. S., D. M. Fleming, and M. C. Zambon. 1997. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. *J. Clin. Microbiol.* **35**:2076-2082.
8. Falck, G., J. Gnärpe, and H. Gnärpe. 1997. Prevalence of *Chlamydia pneumoniae* in healthy children and in children with respiratory tract infections. *Pediatr. Infect. Dis. J.* **16**:549-554.

9. **Fan, J. and K. Henrickson.** 1996. Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay. *J. Clin. Microbiol.* **34**:1914-1917.
10. **Garenne, M., C. Ronsmans, H. Campbell.** 1992. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. *World Health Stat. Q.* **45**:180-191.
11. **Gaydos, C. A., T. C. Quinn, and J. J. Elden.** 1992. Identification of *Chlamydia pneumoniae* by DNA amplification of the 16S rRNA gene. *J. Clin. Microbiol.* **30**:796-800.
12. **Gendrel, D., J. Raymond, F. Moulin, J. L. Iniguez, S. Ravilly, F. Habib, P. Lebon, and G. Kalifa.** 1997. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. *Eur. J. Clin. Microbiol. Infect. Dis.* **16**:388-391.
13. **Gilbert, L. L., A. Dakhama, B. M. Bone, E. E. Thomas, and R. G. Hegele.** 1996. Diagnosis of viral respiratory tract infections in children by using a reverse transcription-PCR panel. *J. Clin. Microbiol.* **34**:140-143.
14. **Goo, Y. A., M. K. Hori, J. H. Jr. Voorhies, C. C. Kuo, S. P. Wang, L. A. Campbell.** 1995. Failure to detect *Chlamydia pneumoniae* in ear fluids from children with otitis media. *Pediatr. Infect. Dis. J.* **14**:1000-1001.
15. **Hassan-King M., I. Baldeh, R. Adegbola, C. Omosigho, S. O. Usen, A. Oparaugo, B. M. Greenwood.** 1996. Detection of *Haemophilus influenzae* and *Streptococcus pneumoniae* DNA in blood culture by a single PCR assay. *J. Clin. Microbiol.* **34**:2030-2032.

16. Hassan-King M., R. Adegbola, I. Baldeh, K. Mulholland, C. Omosigho, A. Oparaugo, S. Usen, A. Palmer, G. Schneider, O. Secka, M. Weber, B. Greenwood. 1998. A polymerase chain reaction for the diagnosis of Haemophilus influenzae type b disease in children and its evaluation during a vaccine trial. *Pediatr. Infect. Dis. J.* 17:309-312.
17. Hemming, V. G. 1994. Viral respiratory diseases in children: classification, etiology, epidemiology and risk factors. *J. Pediatr.* 124: S13-16.
18. Hlerholzer, J. C., P. E. Halonen, P. O. Dahlen, P. G. Bingham, M. M. McDonough. 1993. Detection of adenovirus in clinical specimens by polymerase chain reaction and liquid-phase hybridization quantitated by time-resolved fluorometry. *J. Clin. Microbiol.* 31:1886-1891.
19. Hinman, A. R.. 1998. Global progress in infectious diseases control. *Vaccine* 16:1116-1121.
20. Karron, R. A., K. L. O'Brien, J. L. Froehlich, and V. A. Brown. 1992. Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward. *J. Inf. Dis.* 167:1441-1445.
21. Kawasaki, E. S. 1990. Amplification of RNA, p.21-27. In M. A. Innis, D. H. Gelfand, J. J. Sninsky and T.J. White (ed.), *PCR protocols: A guide to methods and applications*. Academic Press.
-
22. Marx, A., T. J. Török, R. C. Holman, M. J. Clarke, and L. J. Anderson. (1997). Pediatric Hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenzavirus 1 epidemics. *J. Infect. Dis.* 176: 1423-1427.
23. Messmer, T.O., S. K. Skelton, J. F. Moroney, H. Daugharty, and B. S. Fields. 1997. Application of a nested, multiplex PCR to psittacosis outbreaks. *J. Clin. Microbiol.* 35:2043-2046.

24. Nohynek, H., J. Eskola, M. Kleemola, E. Jalonen, P. Saikku, M. Leinonen. 1995. Bacterial antibody assays in the diagnosis of acute lower respiratory tract infection in children. *Pediatr. Infect. Dis. J.* 14: 478-484.
25. Paton, A. W., J. C. Paton, A. J. Lawrence, P. N. Goldwater, and R. J. Harris. 1992. Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by reverse transcription and polymerase chain reaction amplification. *J. Clin. Microbiol.* 30:901-904.
26. Reznikov, M., T. K. Blackmore, J. J. Finlay-Jones, and D. L. Gordon. 1995. Comparison of nasopharyngeal and throat swab specimens in a polymerase chain reaction-based test for *Mycoplasma pneumoniae*. *Eur. J. Clin. Microbiol. Infect. Dis.* 14:58-61.
27. Rotbart, H. A. 1990. Enzymatic RNA amplification of the enteroviruses. *J. Clin. Microbiol.* 28:438-442.
28. Rotbart, H. A., M. H. Sawyer, S. Fast, C. Lewinski, N. Murphy, E. F. Keyser, J. Spadaro, S. Y. Kao, M. Loeffelholz. 1994. Diagnosis of enteroviral meningitis by using PCR with a colorimetric microwell detection assay. *J. Clin. Microbiol.* 32:2590-2592.
29. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, H. A. Erlich. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 239:487-491.
30. Saiki, R. K. 1990. Amplification of genomic DNA., p.13-20. *In* M. A. Innis, D. H. Gelfand, J. J. Sninsky and T.J. White (ed.), *PCR protocols: A guide to methods and applications*. Academic Press.
31. Saikku, P. 1997. Atypical respiratory pathogens. *Clin. Microbiol. Inf.* 3:599-604

32. **Sambrook, J., E. F. Fritsch, and T. Maniatis.** 1989. Molecular cloning: A Laboratory Manual. pp 6.5, and 6.1-6.19. Cold spring Harbor Laboratory, Cold Spring Harbor, NY.
33. **Stauffer, F., H. Haber, A. Rieger, R. Mutschlechner, P. Hasenberger, V. J. Tevere, K. K. Young.** 1998. Genus level identification of mycobacteria from clinical specimens by using an easy-to-handle Mycobacterium-specific PCR assay. *J. Clin. Microbiol.* **36**:614-617.
34. **Trollfors, B., and B. A. Claesson.** 1997. Childhood pneumonia: possibilities for aetiological diagnosis. *Baillière's Clinical Paediatrics.* **5**:71-84.
35. **UNICEF.** 1993. Pneumonia: 3.5 millions deaths. *The State of the World's Children.*
36. **Valassina, M., A. M. Cuppone, M. G. Cusi, P. E. Valensin.** 1997. Rapid detection of different RNA respiratory virus species by multiplex RT-PCR: application to clinical specimens. *Clin. Diagn. Virol.* **8**:227-232.
37. **Van Kuppeveld, F. J. M., J. T. M. van der Logt, A. F. Angulo, M. J. van Zoest, W. G. V. Quint, H. G. M. Niesters, J. M. D. Galama, and W. J. G. Melchers.** 1992. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. *Appl. Env. Microbiol.* **58**:2606-2615.
38. **Woo, P. C., S. S. Chiu, W. H. Seto, M. Peiris.** 1997. Cost-effectiveness of rapid diagnosis of viral respiratory tract infections in pediatric patients. *J. Clin. Microbiol.* **35**:1579-1581.

Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Nucleic acid-binding molecules with high affinity and base sequence specificity : intercalating agents covalently linked to oligodeoxynucleotides. *Proc. Natl. Acad. Sci. USA* 81(11):3297-301.

Bej A, Mahbubani M, Miller R, Di Cesare J, Haff L, Atlas R. (1990) Multiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water. *Mol Cell Probes* 4:353-365.

Compton J. (1991) Nucleic acid sequence-based amplification. *Nature* 350: 91-92.

Duck P. (1990) Probe amplifier system based on chimeric cycling oligonucleotides. *Biotechniques* 9: 142-147.

Guatelli J, Whitfield K, Kwoh D, Barringer K, Richman D, Gengeras T. (1990) Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. *Proc Natl Acad Sci USA* 87: 1874-1878.

Kwoh D, Davis G, Whitfield K, Chappelle H, Dimichele L, Gingeras T. (1989) Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. *Proc Natl Acad Sci USA* 86: 1173-1177.

Kwok S, Kellogg D, McKinney N, Spasic D, Goda L, Levenson C, Sinisky J. (1990) Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies. *Nucl. Acids Res.* 18: 999.

Landgren U, Kaiser R, Sanders J, Hood L. (1988) A ligase-mediated gene detection technique. *Science* 241:1077-1080.

Lomeli H, Tyagi S, Pritchard C, Lisardi P, Kramer F. (1989) Quantitative assays based

Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. *Biochemistry* 18(23):5134-43.

Mullis K.B. and Faloona F.A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction (1987). *Methods Enzymol.* **155**: 335-350.

Nielsen P, Egholm M, Berg R, Buchardt O (1993) Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. *Nucleic-Acids-Res.* 21(2):197-200.

Saiki R.K., Walsh P.S., Levenson, C.H. and Erlich H.A. Genetic analysis of amplified DNA with immobilizes sequence-specific oligonucleotide probes (1989). *Proc. Natl.*

Acad. Sci. USA **86**: 6230-6234.

Sambrook J, Fritsch E, Maniatis T (1989) *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Stuyver L, Rossau R, Wyseur A et al (1993) Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. *J. Gen. Virol.* **74**: 1093-1102

Wu D, Wallace B. (1989) The ligation amplification reaction (LAR) - amplification of specific DNA sequences using sequential rounds of template-dependent ligation. *Genomics* **4**:560-569. Yang S.Y. A standardised method for detection of HLA-A and HLA-B alleles by one-dimensional isoelectric focusing (IEF) gel electrophoresis. *Immunobiology of HLA. Histocompatibility testing 1987* (ed. B. Dupont). Springer-Verlag, New York, pp. 332-335.

CLAIMS

1. Method for the detection of acute respiratory tract infection comprising the simultaneous amplification of several target nucleotide sequences present in a biological sample by means of a primer mixture comprising at least one primer set from each one of the following gene regions:

- the F1 subunit of the fusion glycoprotein gene for RSV,
- the hemagglutininneuraminidase gene for PIV-1,
- the 5' noncoding region of the PIV-3 fusion protein gene,
- 16 S rRNA sequence for *M. Pneumoniae*,
- 16S rRNA sequence for *C. Pneumoniae*,
- the 5' noncoding region for enterovirus,
- the non-structural protein gene from influenza A,
- the non-structural protein gene from influenza B, and,
- the hexon gene for adenoviruses.

2. Method according to claim 1 wherein said 16S rRNA primers are replaced by primers from the spacer region between the 16S and the 23S rRNA sequences.

3. Method according to claim 1 or 2 wherein in addition also at least one primer pair for the specific detection of *B. Pertussis* and *B. Parapertussis* are used.

4. Method according to any of claims 1 to 3 wherein said primers are chosen from Table 2 or Table 4.

5. Method according to any of claims 1 to 4 wherein said amplified products are subsequently detected using a probe, with said probe being preferably selected from Table 3 or 4.

6. Primer chosen from Table 2 or Table 4.

7. Probe chosen from table 3 or 4.

8. Kit for the detection of acute respiratory tract infection comprising a set of primers for performing a method according to any of claims 1 to 4.

9. Kit for the detection of acute respiratory tract infection comprising a set of probes for performing a method according to claim 5.

10. Kit according to claim 9, wherein said probes are applied as parallel lines on a solid support, preferably on a nylon membrane.

ABSTRACT

The present invention relates to a method for the detection of acute respiratory tract infection comprising the simultaneous amplification of several target nucleotide sequences present in a biological sample by means of a primer mixture comprising at least one primer set from each one of the following gene regions:

- the F1 subunit of the fusion glycoprotein gene for RSV,
- the hemagglutininneuraminidase gene for PIV-1,
- the 5' noncoding region of the PIV-3 fusion protein gene,
- 16 S rRNA sequence for *M. Pneumoniae*,
- 16S rRNA sequence for *C. Pneumoniae*,
- the 5' noncoding region for enterovirus,
- the non-structural protein gene from influenza A,
- the non-structural protein gene from influenza B, and,
- the hexon gene for adenoviruses.

This multiplex RT-PCR method is particularly preferred because it allows to determine the presence of the following micro organisms which infect the respiratory tract of mainly children in one amplification step: RSV, parainfluenza virus, *M. pneumoniae*, *C. pneumoniae*, enterovirus, influenza A and B and adenoviruses.

The present invention also relates to a kit for performing the above-mentioned detection method as well as to the individual probes and primers used therein.

1/4




Figure 1




Figure 2

2/4




Figure 3

3/4




Figure 4

4/4




Figure 5




Figure 6